Open-Label, Phase II, Multicenter Study of Lasofoxifene Plus Abemaciclib for Treating Women With Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation After Disease Progression on Prior Therapies: ELAINE 2
Source : https://pubmed.ncbi.nlm.nih.gov/38072513/
Lasofoxifene plus abemaciclib had an acceptable safety profile, was well tolerated, and exhibited meaningful antitumor activity in women with ESR1-mutated, ER+/HER2- mBC after disease progression on prior CDK4/6i. Observed decreases...
Lasofoxifene plus abemaciclib led to meaningful PFS, ORR, and CBR in ESR1-mutant mBC. Lasofoxifene plus abemaciclib was active for ESR1-mutated breast tumors that progressed with ET and CDK4/6 inhibitors.
Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Breast Cancer and Alternative Treatment Strategies
Source : https://pubmed.ncbi.nlm.nih.gov/38030174/
Breast cancer (BC) is a common malignancy in women, with hormone receptor (HR)-positive subtype responsible for approximately 70% of cases. Currently, patients with metastatic HR-positive BC rely on endocrine therapy...
CDK4/6 inhibitors are currently the effectual standard therapy in combination with endocrine therapy in HR-positive breast cancer. Despite that, issues regarding resistance to CDK4/6 inhibitors in a clinical setting is an inevitable issue.
Should Patients With Hormone Receptor-Positive, HER2-Negative Breast Cancer and One or Two Positive Sentinel Nodes Undergo Axillary Dissection to Determine Candidacy for Adjuvant Abemaciclib?
Source : https://pubmed.ncbi.nlm.nih.gov/38018862/
Patients with one +SLN without HRFs are unlikely to have ≥4 +LNs and should not be subjected to the morbidity of ALND in order to inform candidacy for abemaciclib.
Patients with one +SLN without HRFs are unlikely to have ≥4 +LNs and should not be subjected to the morbidity of ALND to inform candidacy for abemaciclib.
Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors-VagLaser Study Protocol: a Randomized Blinded, Placebo-Controlled Trial
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11656-x
Vaginal CO2 laser therapy is a new treatment option for genitourinary syndrome of menopause. Its potential is particularly interesting in breast cancer survivors, where existing treatment options often are insufficient...
This study will be the first to investigate change in vaginal and urine microbiota during vaginal laser therapy in survivors of breast cancer.
Machine Learning-Based Models for the Prediction of Breast Cancer Recurrence Risk
Source : https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-023-02377-z
Breast cancer is the most common malignancy diagnosed in women worldwide. The prevalence and incidence of breast cancer is increasing every year; therefore, early diagnosis along with suitable relapse detection...
CA125 expression levels affected the risk of recurrence, with higher expression levels associated with a higher five-year risk of recurrence and a shorter progression-free survival in patients.